NCT06632106 - HAIC in Combination with Immune Checkpoint Inhibitors and Tyrosine Kinase Inhibitors for Advanced HCC | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

August 16, 2024

Primary Completion Date

January 30, 2025

Study Completion Date

May 30, 2025

Conditions

Hepatic Arterial Infusion ChemotherapyTyrosine Kinase InhibitorImmune Checkpoint InhibitorsHepatocellular Carcinoma (HCC)

Interventions

PROCEDURE

hepatic artery infusion chemotherapy

Hepatic arterial infusion chemotherapy including FOLFOX and RALOX

DRUG

Tyrosine kinase inhibitor (TKIs)

TKIs including Lenvatinib, Sorafenib, Apatinib, Donafenib, Bevacizumab

DRUG

Immune Checkpoint Inhibitors

ICIs including Camrelizumab, Sintilimab, Tislelizumab, Pembrolizumab, Atezolizumab

Trial Locations (1)

The first hospital of China medical university, Shenyang

All Listed Sponsors

lead

First Hospital of China Medical University

OTHER